NCT03920839 - INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | Biotech Hunter

Timeline

Start Date

July 15, 2019

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions

Advanced and/or Metastatic Solid TumorsStage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung CancerAdvanced/Metastatic Unresectable Malignant Pleural Mesothelioma

Interventions

DRUG

Retifanlimab

INCMGA00012 administered intravenously every 3 weeks.

DRUG

Gemcitabine

Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.

DRUG

Cisplatin

Cisplatin administered intravenously on Day 1 of 21-day cycles.

DRUG

Pemetrexed

Pemetrexed administered intravenously on Day 1 of 21-day cycles.

DRUG

Carboplatin

Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.

DRUG

Paclitaxel

Paclitaxel administered intravenously on Day 1 of 21-day cycles.